1. Home
  2. OMER vs HDL Comparison

OMER vs HDL Comparison

Compare OMER & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$17.33

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

N/A

Current Price

$13.80

Market Cap

723.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
OMER
HDL
Founded
1994
2016
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
844.6M
723.1M
IPO Year
2008
2023

Fundamental Metrics

Financial Performance
Metric
OMER
HDL
Price
$17.33
$13.80
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.50
N/A
AVG Volume (30 Days)
2.0M
1.0K
Earning Date
05-14-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
98.15
N/A
EPS
0.77
N/A
Revenue
$29,868,000.00
N/A
Revenue This Year
N/A
$14.73
Revenue Next Year
$233.22
$12.94
P/E Ratio
$22.49
$55.56
Revenue Growth
N/A
N/A
52 Week Low
$3.94
$12.00
52 Week High
$18.14
$21.21

Technical Indicators

Market Signals
Indicator
OMER
HDL
Relative Strength Index (RSI) 83.27 56.47
Support Level $9.12 $13.21
Resistance Level $17.65 $13.87
Average True Range (ATR) 0.75 0.15
MACD 0.52 0.08
Stochastic Oscillator 87.76 83.33

Price Performance

Historical Comparison
OMER
HDL

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

Share on Social Networks: